Clinical and translational attributes of immune-related adverse events

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database

Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?

Impact of aging on immune-related adverse events generated by anti–programmed death (ligand)PD-(L)1 therapies